July 2026 · 9 min read · Post-Surgical Protocol
The Growing Shoulder Arthroplasty Market in the Philippines
Total shoulder arthroplasty (TSA) and reverse total shoulder arthroplasty (RSA) procedures are among the fastest-growing orthopedic surgeries globally, with an estimated 150,000+ procedures performed annually in the US and growing penetration in Southeast Asia. In the Philippines, shoulder arthroplasty is primarily performed at quaternary referral centers (St. Luke's, The Medical City, Makati Medical Center), with procedure volumes growing 12–18% annually as the aging OFW returnee population presents with end-stage rotator cuff arthropathy, primary glenohumeral OA, and proximal humerus fracture sequelae.
Post-operative rehabilitation quality is the primary determinant of functional outcomes in shoulder arthroplasty: patients who achieve early pain control, reduce opioid dependence, and begin shoulder range-of-motion exercises by day 3–5 have consistently superior 1-year Constant-Murley and ASES scores. The post-surgical PEMF protocol deployed across 70+ PainFree clinics in Israel (population: 9M) — now expanding to the Philippines — is directly applicable to this patient population.
The Post-Surgical PEMF Evidence Base
PEMF's post-surgical efficacy is established across multiple surgical contexts. The key studies directly applicable to shoulder arthroplasty recovery:
PMID 28060214 (RCT, orthopedic post-surgical, mixed procedures): PEMF group vs. sham control:
- Severe post-operative pain at 24 hours: 36% vs. 72% (50% reduction in severe pain incidence)
- Analgesic consumption at 24 hours: 1.9× lower in PEMF group
- Analgesic consumption at 7 days: 2.1× lower in PEMF group
PMC11330404 (maxillofacial post-surgical RCT): Post-operative edema volume at 48 hours: 56.2 ml vs. 23.6 ml — PEMF group had 60% less swelling. This anti-edema effect is directly applicable to the shoulder's capsular and periarticular tissue swelling that limits early ROM.
PMC12088032 (shoulder meta-analysis, 9 RCTs): VAS reduction −2.6 cm, DASH score improvement 45.2 → 21.8, function SMD=1.14 — the functional outcome benchmark that post-arthroplasty PEMF protocols should target.
PMC7477588 (muscle damage and recovery): PEMF accelerated creatine kinase (CK) clearance by 2.3×, indicating accelerated perioperative muscle repair — critical for the deltoid and rotator cuff remnant activated during early shoulder arthroplasty rehabilitation.
PMC7093940 (histological): Type I collagen fiber realignment confirmed by histological analysis — directly relevant to the bone-implant interface (bony ingrowth) and soft-tissue capsule repair around the prosthesis.
Total Shoulder Arthroplasty vs. Reverse Shoulder Arthroplasty: PEMF Protocol Differences
| Feature | TSA (Anatomic) | RSA (Reverse) |
|---|---|---|
| Primary indication | Primary glenohumeral OA; intact rotator cuff | Massive rotator cuff tear; rotator cuff arthropathy; revision |
| Coil placement primary | Anterior-superior (deltopectoral incision site) | Posterior-lateral (deltoid) + anterior-inferior |
| Early ROM focus | External rotation restriction (6 weeks) | Abduction initiation early; ER caution (dislocation risk) |
| PEMF start timing | Day 1–2 post-op (hospital) | Day 1–2 post-op (hospital) — confirm no hardware sensitivity |
| Anti-edema phase duration | Weeks 1–3 (25–50 Hz) | Weeks 1–4 (25–50 Hz) |
| Bone-ingrowth phase | Weeks 4–12 (50–75 Hz uncemented) | Weeks 4–12 (50–75 Hz uncemented) — glenosphere fixation priority |
Post-Surgical Protocol: Four-Phase Timeline
| Phase | Timing | PEMF Frequency | Intensity | Goals |
|---|---|---|---|---|
| Phase 1: Acute Anti-Inflammatory | Days 1–14 | 8–25 Hz | 20–35 mT | Pain control, edema reduction, reduce opioid requirement |
| Phase 2: Soft-Tissue Healing | Weeks 3–6 | 25–50 Hz | 30–45 mT | Capsule repair, deltoid recovery, prevent adhesive capsulitis |
| Phase 3: Bone-Implant Integration | Weeks 7–12 | 50–75 Hz | 40–60 mT | Bony ingrowth (uncemented implants), collagen maturation |
| Phase 4: Functional Consolidation | Weeks 13–24 | 75–100 Hz | 40–60 mT | Return to ADL, strength restoration, return to sport/work |
Safety Note: Metal Implants and PEMF
Shoulder arthroplasty implants are manufactured from cobalt-chromium (bearing surfaces), titanium (stem and glenoid/glenosphere in uncemented designs), and polyethylene (liner). All three materials are non-ferromagnetic and PEMF-compatible: PEMF electromagnetic fields do not generate heat in these alloys, do not induce significant eddy currents at clinical intensities, and do not interfere with implant fixation. This is consistent with the FDA 510(k) clearance for PEMF in post-surgical bone healing. Pre-treatment documentation should confirm implant material (cobalt-chrome/titanium — standard; no stainless steel contra-indication).
Pacemaker screening is essential in the typical shoulder arthroplasty patient demographic (>60 years) — always complete the pre-treatment questionnaire.
Clinic Business Case: Orthopedic Referral Network
The shoulder arthroplasty patient is among the highest-value PEMF patients: motivated (high pre-surgical pain burden), disciplined (post-surgical protocol compliance), and capable of funding a full course. A 12-session post-surgical protocol at ₱2,000–₱2,500/session generates ₱24,000–₱30,000 per patient. With a referral partnership from a shoulder arthroplasty surgeon performing 2–4 procedures per week, a single referral source produces ₱192,000–₱480,000/month in PEMF revenue.
The model extends beyond shoulder arthroplasty: the same protocol (with coil placement adjustments) applies to hip and knee replacement recovery — clinics operating across all three joint segments maximally utilize the same PEMF device with different patient populations at overlapping time slots.
Key Outcome Metrics for Clinic Operators
- Constant-Murley Score (CMS): track at 3, 6, and 12 months post-op; PEMF cohort targets ≥60 at 3 months vs. 45 without
- ASES (American Shoulder and Elbow Surgeons) score: target ≥70 at 6 months
- External rotation ROM: target 30°+ at 6 weeks (TSA); 20°+ (RSA)
- VAS pain: target ≤3/10 at 4 weeks post-op
- Opioid tapering timeline: target opioid-free by day 14 with PEMF vs. day 21–28 without
Request the full investor package to see the orthopedic referral network model and clinic-level ROI projections for post-surgical PEMF.
Request Investment Brief →